Invesco Portfolio holdings
Invesco is an investment management company that launched the Invesco QQQ exchange-traded fund in 1999, back when it operated as Amvescap. Invesco QQQ tracks the Nasdaq-100 index of companies listed on Nasdaq. Invesco traces its roots to H. Lotery & Co., a UK advisory firm formed in 1935, and in 1978 Charles Brady and eight partners bought the money management arm of Citizens & Southern National Bank, then called INVESCO. It bought PowerShares Capital Management, sponsor of 36 exchange-traded funds, in 2006, and in 2007 it went back to the Invesco name and moved its legal home to Bermuda. Its 2009 purchase of Morgan Stanley's retail unit brought in Van Kampen Investments, and in 2019 it acquired OppenheimerFunds from Massachusetts Mutual Life Insurance Company. It serves retail and institutional investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sandisk
SNDK
|
+$6.35B |
| 2 |
HONA
Honeywell Aerospace
HONA
|
+$2.84B |
| 3 |
Arm
ARM
|
+$1.84B |
| 4 |
Lumentum
LITE
|
+$1.78B |
| 5 |
Teradyne
TER
|
+$1.57B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco NASDAQ 100 ETF
QQQM
|
+$2.26B |
| 2 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$2.2B |
| 3 |
Honeywell
HON
|
+$2.2B |
| 4 |
Dell
DELL
|
+$1.69B |
| 5 |
Insmed
INSM
|
+$744M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 44.02% |
| 2 | Consumer Discretionary | 9.38% |
| 3 | Communication Services | 9.23% |
| 4 | Industrials | 8.59% |
| 5 | Healthcare | 7.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3651
Palladyne AI
PDYN
$163M
| $116K | ﹤0.01% |
19,011
+5,512
| +41% | +$36.5K |
2025 Q2
4 quarters
|
|
3652
Sight Sciences
SGHT
$513M
| $115K | ﹤0.01% |
21,274
+8,236
| +63% | +$37.9K |
2025 Q4
2 quarters
|
|
3653
Inspired Entertainment
INSE
$94.1M
| $112K | ﹤0.01% |
13,619
-6,854
| -33% | -$51K |
2022 Q2
16 quarters
|
|
3654
Rimini Street
RMNI
$463M
| $112K | ﹤0.01% |
26,268
+7,635
| +41% | +$28.9K |
2020 Q4
22 quarters
|
|
3655
Forrester Research
FORR
$210M
| $111K | ﹤0.01% |
13,211
-7,390
| -36% | -$48.3K |
2013 Q2
52 quarters
|
|
3656
Playtika
PLTK
$755M
| $111K | ﹤0.01% |
29,774
-12,637
| -30% | -$43.7K |
2021 Q1
21 quarters
|
|
3657
Waterdrop
WDH
$359M
| $110K | ﹤0.01% |
97,672
-13,564
| -12% | -$20.6K |
2025 Q2
4 quarters
|
|
3658
Companhia Siderúrgica Nacional
SID
$948M
| $109K | ﹤0.01% |
118,968
-5,078
| -4% | -$6.36K |
2013 Q2
52 quarters
|
|
3659
Orchestra BioMed
OBIO
$355M
| $107K | ﹤0.01% |
+24,689
| New | +$101K |
2026 Q2
0 quarters
|
|
3660
Autolus Therapeutics
AUTL
$405M
| $106K | ﹤0.01% |
66,447
+13,294
| +25% | +$20.9K |
2023 Q2
12 quarters
|
|
3661
Bicycle Therapeutics
BCYC
$257M
| $105K | ﹤0.01% |
24,802
+9,735
| +65% | +$44.6K |
2025 Q4
2 quarters
|
|
3662
Innoviz Technologies
INVZ
$68.6M
| $105K | ﹤0.01% |
137,915
+55,000
| +66% | +$37.6K |
2025 Q2
4 quarters
|
|
3663
Reservoir Media
RSVR
$628M
| $103K | ﹤0.01% |
10,440
-2,891
| -22% | -$29.2K |
2022 Q2
16 quarters
|
|
3664
SKYX Platforms
SKYX
$125M
| $103K | ﹤0.01% |
93,213
+58,398
| +168% | +$64.7K |
2025 Q2
4 quarters
|
|
3665
Profound Medical
PROF
$240M
| $103K | ﹤0.01% |
+15,454
| New | +$104K |
2026 Q2
0 quarters
|
|
3666
Protara Therapeutics
TARA
$147M
| $103K | ﹤0.01% |
26,856
+8,895
| +50% | +$42.3K |
2025 Q2
4 quarters
|
|
3667
Seres Therapeutics
MCRB
$17.8M
| $102K | ﹤0.01% |
12,974
-1,573
| -11% | -$12K |
2025 Q3
3 quarters
|
|
3668
Microbot Medical
MBOT
$73.2M
| $102K | ﹤0.01% |
52,201
+22,781
| +77% | +$46.4K |
2025 Q4
2 quarters
|
|
3669
Asure Software
ASUR
$272M
| $100K | ﹤0.01% |
12,650
+1,541
| +14% | +$13.4K |
2025 Q2
4 quarters
|
|
3670
American Resources Corp
AREC
$131M
| $99.2K | ﹤0.01% |
+46,144
| New | +$103K |
2026 Q2
0 quarters
|
|
3671
Exagen
XGN
$208M
| $98.3K | ﹤0.01% |
+21,133
| New | +$79.6K |
2026 Q2
0 quarters
|
|
3672
InflaRx
IFRX
$245M
| $98.2K | ﹤0.01% |
+43,851
| New | +$82.4K |
2026 Q2
0 quarters
|
|
3673
CAMP4 Therapeutics
CAMP
$249M
| $98K | ﹤0.01% |
+22,425
| New | +$96.7K |
2026 Q2
0 quarters
|
|
3674
Arq
ARQ
$77.3M
| $97.2K | ﹤0.01% |
38,132
+394
| +1% | +$978 |
2024 Q2
8 quarters
|
|
3675
Oncolytics Biotech
ONCY
$55.8M
| $96.1K | ﹤0.01% |
+101,195
| New | +$93.8K |
2026 Q2
0 quarters
|
|
Similar funds
Invesco's Q2 2026 Portfolio in Review
As of Q2 2026, Invesco held 3,969 positions worth $1.26T, up 23% from $1.02T the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Invesco's Q2 2026 filing shows 214 new, 1,806 increased, 1,705 reduced and 150 closed positions. Its largest new stake was Honeywell Aerospace: 12,884,435 shares worth $2.85B. The largest sale was Invesco NASDAQ 100 ETF, an estimated $2.26B.
By sector, the portfolio is most concentrated in Technology at 44% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Invesco's largest Q2 2026 buy was Honeywell Aerospace: 12,884,435 shares worth $2.85B.
- Invesco added most to Sandisk in Q2 2026, an estimated $6.35B increase.
- Invesco's biggest Q2 2026 reduction was Invesco NASDAQ 100 ETF, cutting an estimated $2.26B.
- Invesco fully exited Coterra Energy in Q2 2026, selling an estimated $394M.
- Invesco's ten largest holdings make up 29% of its $1.26T portfolio in Q2 2026.
- Invesco opened 214 new positions and closed 150 in Q2 2026.
- Invesco's portfolio value rose 23% quarter-over-quarter to $1.26T.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.